TY - JOUR
T1 - A prospective, multisite implementation-efficacy trial of a collaborative prescriber-pharmacist model of care for Medication Assisted Treatment for Opioid Dependence
T2 - Protocol for the EPIC-MATOD study
AU - Nielsen, Suzanne
AU - Cheetham, Ali
AU - Jackson, John
AU - Lord, Sarah
AU - Petrie, Dennis
AU - Jacka, David
AU - Picco, Louisa
AU - Morgan, Kirsty
N1 - Funding Information:
This study is supported by the Victorian Government through an Alcohol and Drug Research Innovation Agenda (ADRIA) Research Grant. SN is the recipient of an NHMRC Research Fellowship ( 1163961 ).
Funding Information:
The study is sponsored and managed by the Monash University. This study has received ethics approval from Monash University Human Research Ethics Committee (Ref. HREC 27616). The study was registered on https://www.anzctr.org.au (ACTRN12621000871842). The study will be conducted in accordance with ICH-GCP guidelines, the Declaration of Helsinki, and all applicable local ethical and regulatory requirements. All participants must provide written informed consent. The findings will be disseminated via publications in a peer-reviewed journals and relevant scientific conference presentations and patient forums.This study is supported by the Victorian Government through an Alcohol and Drug Research Innovation Agenda (ADRIA) Research Grant. SN is the recipient of an NHMRC Research Fellowship (1163961).We wish to acknowledge the contributions of the EPIC-MATOD Clinical Reference Group, members not listed as authors on the current manuscript: Ferghal Armstrong, Angelo Pricolo, Anna Theophilos, and Rob Weiss. The authors would also like to thank all the participants in the settings assessment which was pivotal in informing the study design, and members of the and project steering group. EPIC MATOD is supported by the Victorian Government. The Monash Addiction Research Centre acknowledges the support of the RAD-FMP Project (an initiative of FMP-PCP, under the auspices of Peninsula Health) and the Frankston Revitalisation Board.
Funding Information:
EPIC MATOD is supported by the Victorian Government . The Monash Addiction Research Centre acknowledges the support of the RAD-FMP Project (an initiative of FMP-PCP, under the auspices of Peninsula Health) and the Frankston Revitalisation Board.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/8
Y1 - 2022/8
N2 - Background: Medication Assisted Treatment for Opioid Dependence (MATOD) is clinically effective and cost effective, yet a lack of MATOD prescribers in the community limits access to this treatment in Australia. These shortages are often greatest in regional and rural areas. Objective(s): The Enhancing Pharmacist Involvement in Care (EPIC)-MATOD study will evaluate clinical and implementation outcomes among people with opioid dependence receiving MATOD through a collaborative pharmacist-prescriber model of care across multiple sites in a regional location (encompassing a mix of metropolitan and non-metropolitan areas) of Victoria, Australia. Methods and analysis: The EPIC-MATOD study is a prospective, multisite, implementation trial of collaborative MATOD care. Pharmacists and prescribers will be recruited through the local network of opioid pharmacotherapy providers. Patients will be recruited through participating healthcare providers. After induction into the collaborative care model, patients and healthcare professionals will be followed up over 6- (patients) and 12-months (pharmacists and prescribers) in a hybrid implementation-efficacy study, with outcomes mapped to the RE-AIM framework. The primary clinical efficacy endpoint is patient retention in treatment at 26 weeks. The primary implementation outcome is treatment capacity, based on prescriber time required to provide treatment through collaborative care compared with traditional care. Secondary clinical endpoints include attendance for dosing and clinical reviews, substance use, mental and physical health and overall well-being. Implementation costs, acceptability, and provider engagement in collaborative care will be used as secondary implementation outcome indicators. Time and costs associated with collaborative care, and health service utilisation, will also be estimated. Project impact: The study will provide important information on outcomes and acceptability of collaborative care for MATOD, as well as the cost and key considerations in delivering a collaborative model of care in Australia and other countries where similar treatment barriers exist.
AB - Background: Medication Assisted Treatment for Opioid Dependence (MATOD) is clinically effective and cost effective, yet a lack of MATOD prescribers in the community limits access to this treatment in Australia. These shortages are often greatest in regional and rural areas. Objective(s): The Enhancing Pharmacist Involvement in Care (EPIC)-MATOD study will evaluate clinical and implementation outcomes among people with opioid dependence receiving MATOD through a collaborative pharmacist-prescriber model of care across multiple sites in a regional location (encompassing a mix of metropolitan and non-metropolitan areas) of Victoria, Australia. Methods and analysis: The EPIC-MATOD study is a prospective, multisite, implementation trial of collaborative MATOD care. Pharmacists and prescribers will be recruited through the local network of opioid pharmacotherapy providers. Patients will be recruited through participating healthcare providers. After induction into the collaborative care model, patients and healthcare professionals will be followed up over 6- (patients) and 12-months (pharmacists and prescribers) in a hybrid implementation-efficacy study, with outcomes mapped to the RE-AIM framework. The primary clinical efficacy endpoint is patient retention in treatment at 26 weeks. The primary implementation outcome is treatment capacity, based on prescriber time required to provide treatment through collaborative care compared with traditional care. Secondary clinical endpoints include attendance for dosing and clinical reviews, substance use, mental and physical health and overall well-being. Implementation costs, acceptability, and provider engagement in collaborative care will be used as secondary implementation outcome indicators. Time and costs associated with collaborative care, and health service utilisation, will also be estimated. Project impact: The study will provide important information on outcomes and acceptability of collaborative care for MATOD, as well as the cost and key considerations in delivering a collaborative model of care in Australia and other countries where similar treatment barriers exist.
KW - Collaborative care
KW - Community pharmacy
KW - Implementation-efficiency trial
KW - MOUD
KW - Opioid agonist treatment
KW - Study protocol
UR - http://www.scopus.com/inward/record.url?scp=85121332209&partnerID=8YFLogxK
U2 - 10.1016/j.sapharm.2021.11.007
DO - 10.1016/j.sapharm.2021.11.007
M3 - Article
C2 - 34924314
AN - SCOPUS:85121332209
SN - 1551-7411
VL - 18
SP - 3394
EP - 3401
JO - Research in Social and Administrative Pharmacy
JF - Research in Social and Administrative Pharmacy
IS - 8
ER -